VIB and V-Bio Ventures have both participated in a series A round for Muna Therapeutics, the result of a merger of two recent spinouts.
Muna Therapeutics, a Denmark-based developer of treatments for neurodegenerative diseases, closed a $73m series A round today backed by VIB and its venture capital affiliate V-Bio Ventures.
Pharmaceutical firm Novo, Sofinnova Partners, Droia Ventures and LSP Dementia co-led the round, with additional participation from Sanofi Ventures, the strategic investment arm of pharmaceutical firm Sanofi, Polaris Partners and Polaris Innovation Fund.
Muna Therapeutics is focused on neurodegenerative diseases for which no cure is currently available and for which palliative…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
